Pfizer secures EC approval for VYNDAQEL to treat ATTR-CM
VYNDAQEL is the only EC-approved medicine to reduce mortality and frequency of cardiovascular-related hospitalizations in adults with hereditary…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Feb 20
VYNDAQEL is the only EC-approved medicine to reduce mortality and frequency of cardiovascular-related hospitalizations in adults with hereditary…
18 Feb 20
The EC approval is supported by the results from the Phase III HAWK and HARRIER clinical trials, in…
18 Feb 20
The FDA approval provides OTC access to the Voltaren Arthritis Pain, which has been available only with a…
17 Feb 20
The regulatory approval indicated Tecentriq plus chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in…
14 Feb 20
Bristol-Myers Squibb has filed a biologics license application (BLA) with the FDA, which has been accepted by the…
13 Feb 20
Ripretinib is an investigational broad-spectrum KIT and PDGFRα inhibitor, intended for the treatment of advanced gastrointestinal stromal tumours…
12 Feb 20
Regulatory bodies need to be clearer on how pharma companies can test parenteral medication more effectively, says Novo…
11 Feb 20
PEMFEXY is a pemetrexed injection ready-to-dilute formulation for locally advanced (metastatic) non-squamous non-small cell lung cancer
Four plaintiffs with mesothelioma first accused Johnson & Johnson of covering up the fact its Baby Powder talc…
31 Jan 20
Evrenzo is indicated for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis dependent (NDD)…